Mylan Gets Some Parts Of Investors' EpiPen Suit Trimmed
Law360 (March 29, 2019, 9:37 PM EDT) -- After trimming some claims and statements, a New York federal judge said Friday that he would not dismiss all of the new claims in an amended investor suit against Mylan NV over allegedly anti-competitive behavior involving its EpiPen epinephrine auto-injector.
After U.S. District Judge J. Paul Oetken found issues with claims in the proposed securities class action a year ago, investors came back to the court the following July with a beefed-up complaint and fresh allegations, including that Mylan offered massive rebates on EpiPens conditioned on an exclusion of a competitor's products.
The rebate scheme was adequately alleged to have blocked...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!